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Exposure tomaternal cortisol plays a crucial role in fetal organogenesis. However, fetal overexposure to cortisol has been linked to a
range of short- and long-term adverse outcomes.Normally, this is prevented by the expression of an enzyme in the placenta called 11-
beta hydroxysteroid dehydrogenase type 2 (11𝛽-HSD2) which converts active cortisol to its inactive metabolite cortisone. Placental
11𝛽-HSD2 is known to be reduced in a number of adverse pregnancy complications, possibly through an epigenetic mechanism.
As a result, a number of pan-HDAC inhibitors have been examined for their ability to promote 11𝛽-HSD2 expression. However, it
is not known if the effects of pan-HDAC inhibition are a general phenomenon or if the effects are dependent upon a specific class
of HDACs. Here, we examined the ability of pan- and class-specific HDAC inhibitors to regulate 11𝛽-HSD2 expression in JEG3
cells. We find that pan-, class I, or class IIa HDAC inhibition promoted 11𝛽-HSD2 expression and prevented cortisol or interleukin-
1𝛽-induced decrease in its expression. These results demonstrate that targeting a specific class of HDACs can promote 11𝛽-HSD2
expression in JEG3 cells. This adds to the growing body of evidence suggesting that HDACs may be crucial in maintaining normal
fetal development.
1. Introduction
The glucocorticoid hypothesis proposes that overexposure of
the fetus to glucocorticoids may produce long lasting effects
on fetal development that subsequently increase disease risk
later in life [1]. The glucocorticoid hypothesis is affirmed by
studies that have shown that elevated maternal cortisol is
associated with heightened HPA activity [2] and alterations
in brain structure [3] in affected offspring. At the core of
this process is the placental enzyme 11𝛽-hydroxysteroid dehy-
drogenase type 2 (11𝛽-HSD2), an enzyme that is expressed
primarily within the syncytiotrophoblast of the placenta
where it catalyses the conversion of active cortisol into its
inactive product cortisone, thereby controlling the levels of
cortisol that reach the fetus [4]. A number of preclinical
and clinical studies have demonstrated a reduction in the
placental expression of 11𝛽-HSD2 following exposure to pre-
natal stress [5], anxiety [6], and following maternal infection
[7]. In addition to this, placental HSD11B2 mRNA levels are
reduced in pregnancy complications such as preeclampsia
[8], intrauterine growth restriction (IUGR) [9], preterm birth
(PTB) [10], and low birth weight (LBW) [11].
A complex repertoire of molecular pathways have been
shown to be involved in regulating placentalHSD11B2 expres-
sion. Inhibition of the mitogen-activated protein kinases
(MAPK) ERK1/2 increases HSD11B2 expression [12], whilst
suppressing p38 reduces 11𝛽-HSD2 activity [13]. HSD11B2 is
increased by activation of peroxisome proliferator-activated
receptor delta (PPAR𝛿) [14] through recruitment of the SP1
transcription factor (TF) [15]. Similarly, activation of the
hedgehog signalling [16] and forskolin-induced activation
of the cyclic AMP (cAMP) pathway increases HSD11B2
expression [17]. More recently, epigenetic mechanisms have
been linked to 11𝛽-HSD2 regulation. The most widely stud-
ied epigenetic mechanisms are DNA methylation and his-
tone acetylation. Histone acetylation is regulated by histone
Hindawi
International Journal of Cell Biology
Volume 2017, Article ID 6169310, 10 pages
https://doi.org/10.1155/2017/6169310
2 International Journal of Cell Biology
acetyl transferase (HATs) and histone deacetylase (HDACs)
enzymes. HATs add acetyl groups onto the N-terminal tail
of histone proteins which increases gene expression [18].
HDACs remove them, thereby repressing transcription [19].
In humans, 18 HDACs have been discovered and they are
classed into four main families: class I (HDACs 1, 2, 3, and
8), class II (HDACs 4, 5, 6, 7, 9, and 10), class III (SIRT1,
SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, and SIRT7), and class
IV (HDAC 11) [20].
Recently, a significant emphasis has been placed on in
vitro studies to tease apart the precise epigenetic mechanisms
involved in regulating placental 11𝛽-HSD2 expression. Global
knock down of DNA methylation using the demethylating
agent 5-aza-2󸀠-deoxycytidine (5-aza) in JEG-3 cells has been
shown to increase the expression of a number steroido-
genic genes including HSD11B2, indicating a direct link
for regulation of HSD11B2 expression by methylation [21].
Despite advancements being made in understanding the
role of methylation in 11𝛽-HSD2 expression, little focus has
been placed on examining the role that HDACs play in
regulating 11𝛽-HSD2. The present study aimed to investigate
the role of histone acetylation in regulating basal and stressor-
induced changes in 11𝛽-HSD2 protein expression in an in
vitro placenta model using small molecule pharmacological
inhibitors.
2. Methods
2.1. Cell Culture and Treatment. JEG-3 cells were grown in
Dulbecco’s modified Eagle’s medium (DMEM): F12 (Sigma),
with 10% fetal calf serum (FCS), 100 nM L-Glutamine,
100U/ml penicillin, and 10 𝜇g/ml streptomycin (Sigma).
Cells were maintained at 37∘C in a humidified atmosphere of
5% CO2. 50,000 cells per well were plated on a 24-well plate
and were treated with 1, 5, or 10 𝜇M of MC1568, MS275, or
SAHA (Selleckchem).Where indicated, 10 ng/ml interleukin-
1𝛽 (IL-1𝛽; Promokine) or 2𝜇M cortisol (Cort; Santa Cruz)
was added for 24 h before HDAC inhibitor (HDI).
2.2. MTT Assay. To assess cell viability, a thiazolyl blue
tetrazolium bromide (MTT) solution was added to the cells
at a concentration of 1mg/ml in HBSS (Sigma). Following
a 2-hour (h) incubation at 37∘C, the cells were lysed in
DMSO (Sigma). Absorbance was measured at a wavelength
of 540 nm with a reference wavelength of 630 nm.
2.3. Immunocytochemistry. At the experimental end point,
cultures were fixed in 4% paraformaldehyde (PFA) in PBS
for 10min. Following 3 × 5min washes in 10mM PBS con-
taining 0.02% Triton X-100 (PBS-T), cultures were incubated
in blocking solution (5% BSA in PBS-T) for 1 h at room
temperature.Where indicated, cultures were incubated in the
following primary antibodies: 11𝛽-HSD2 (1 : 250; Santa Cruz),
AcH3 (1 : 250; Santa Cruz), GR (1 : 250; Santa Cruz), or IL1R1
(1 : 250; Invitrogen) diluted in 1% BSA in 10mM PBS at 4∘C
for 16 h. Following 3 × 5min washes in PBS-T, cells were
incubated in the appropriate Alexa Fluor 488-conjugated or
594-conjugated secondary antibodies (1 : 1000; Invitrogen)
diluted in 1% BSA in 10mM PBS at room temperature
for 2 h. Cultures were counterstained with DAPI (1 : 3000;
Sigma). Cells were imaged under an Olympus IX70 inverted
microscope with Olympus DP70 camera and AnalysisD
software.
2.4. RNA Extraction and Real-Time PCR. RNAwas extracted
from JEG-3 cells 24 hours after seeding and term human
placental tissue using Trizol Reagent (Life Technologies).
Placental tissue was homogenised with a pestle and mortar
and JEG-3 cells were removed from flasks by scraping and
incubated in Trizol for 10min and RNA extraction proceeded
according to the manufacturer’s instructions. 500 ng of RNA
was reverse-transcribed using a high capacity cDNA Reverse
Transcription Kit (Applied Biosystems) in a 20 𝜇l reaction
mixture consisting of 2.0 𝜇l 10x RT Buffer, 0.8 𝜇l 25x dNTP
mix (100mM), 2.0 𝜇l 10x RT Random Primers, 1.0𝜇l Reverse
Transcriptase, and 4.2 𝜇l Nuclease-free H2O, using the fol-
lowing parameters: 25∘C for 10min; 37∘C for 120min; 85∘C
for 5min; 4∘C for at least 10min. The cDNA was stored at
−80∘C prior to use. For real-time PCR, samples were run in
duplicate using TaqMan Gene Expression Assay (Applied
Biosystems) forHSD11B2 using 18S as a reference gene under
the following parameters: 50∘C for 2min; 95∘C for 10min; 40
repetitions of 95∘C for 15 s; and annealing/elongating at 60∘C
for 1min.
2.5. Immunohistochemistry. Histological placental sections
(6 𝜇M) were incubated in blocking solution (5% bovine
serum albumin (BSA)) for 1 h at room temperature. Sections
were treated with 10% H2O2 for 5min, washed in 10mM
Phosphate Buffered Saline (PBS), and blocked for 1 h in
10% normal goat serum in 10mM PBS with 0.4% Triton X.
Sections were incubated in primary antibody to 11𝛽-HSD2
(1 : 250; Santa Cruz) in 1% normal goat serum in 10mM
PBS with 0.4% Triton X overnight at 4∘C. Following a 3 ×
10min wash in 10mM PBS, sections were incubated with a
biotinylated secondary antibody (1 : 200; Vector Labs) for 2 h
at room temperature. Following another 3 × 10min wash in
10mMPBS, sections were incubated in ABC solution (1 : 200;
Vector Labs) for 45min at room temperature followed
by immersion in diaminobenzidine substrate/chromogen
reagent for 2-3min at room temperature. Sections were
dehydrated, cleared, mounted, and imaged using anOlympus
AX70 Provis upright microscope.
2.6. Statistical Analysis. For real-time PCR, expression lev-
els were calculated using the 2-delta-Ct threshold method
[22]. For immunocytochemistry, the fluorescence intensity
of individual cells that were immunopositive for 11𝛽-HSD2
or AcH3 was measured by densitometry using Image J
analysis software (Rasband, WJ, http://rsb.info.nih.gov/ij/).
The relative fluorescence intensity of 11𝛽-HSD2 or AcH3
was calculated as the average fluorescence intensity after
subtraction of the background noise. Data was analysed
using GraphPad Prism v 5 (GraphPad Software Inc., San
Diego, California). Where indicated, data was analysed (as
per Section 2.3) with unpaired Student’s 𝑡-test or one-way
ANOVA with Tukey’s post hoc testing. Values of 𝑝 < 0.05
were considered statistically significant.
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Figure 1: (a) Expression of data derived from the BioGPS database showing relative HSD11B2 expression across multiple human tissues.
(b) Real-time PCR showing HSD11B2 expression in the term human placenta and in JEG-3 cells using the 2-delta-Ct method (𝑁 = 3, 𝑝 >
0.05, unpaired Student’s 𝑡-test; housekeeping gene 18S). Representative photomicrographs of (c) a term human placenta and (d) JEG-3 cells
immunocytochemically stained for 11𝛽-HSD2. Scale bar = 50 𝜇m.
3. Results
3.1. Distribution of HSD11B2 in the Human Placenta and JEG-
3 Cells. We utilized the BioGPS database, an online plat-
form that enables the examination of relative levels of gene
expression across multiple human tissues [23]. Using this
directory, we confirmed the highest levels of HSD11B2 in the
placenta, followed by the kidneys, with very little expression
seen in other tissues (Figure 1(a)), which was confirmed by
immunohistochemistry on human term placental samples
(Figure 1(c)). We next aimed to validate the use of the human
choriocarcinoma cell line, JEG-3 cells. JEG-3 cells are awidely
used in vitro model of placental trophoblast cells and have
previously been demonstrated to be an abundant source of
endogenous 11𝛽-HSD2 [24, 25]. In agreement with this, real-
time PCR confirmed the expression of HSD11B2 mRNA in
JEG-3 cells, with placental RNA used as positive control
(Figure 1(b)). Immunohistochemical staining preformed 24
hours after seeding also confirmed abundant expression of
expression of 11𝛽-HSD2 protein in JEG-3 cells (Figure 1(d)).
3.2. Pan-HDAC Inhibition Increases 11𝛽-HSD2 Expression
in JEG-3 Cells. HDACs can be divided into four distinct
families, of particular interest are class I (HDAC1, HDAC2,
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Figure 2: Epigenetic regulation of 11𝛽-HSD2 expression. Graphical representation of (a) 11𝛽-HSD2 and (b) AcH3 expression in JEG-3
cells treated with 0–10𝜇M of SAHA for 24 h. Data are expressed as mean ± SEM. (c) Representative photomicrographs of JEG-3 cells
immunocytochemically stained for 11𝛽-HSD2 (∗𝑝 < 0.05, ∗∗∗𝑝 < 0.001 compared to 0𝜇M; (a) one-way ANOVA with post hoc Tukey’s
and (b) unpaired Student’s 𝑡-test; 25 cells per group per experiment;𝑁 = 3). Scale bar = 50 𝜇m.
HDAC5, and HDAC8) and class II (HDAC5, HDAC6,
HDAC7, HDAC9, and HDAC10) HDACs [26]. We used the
BioGPS database to examine the relative expression levels of
these different HDACs in the human placenta. Class I and
class II HDACs were widely expressed in the placenta (see
Supplementary Figure 1 in Supplementary Material avail-
able online at https://doi.org/10.1155/2017/6169310); however,
HDAC1 (class I) and HDAC5 (class IIa) had the highest
relative levels of expression in the placenta compared to
other tissues (Figures 3(a) and 3(e)). Given the widespread
expression of HDACs, we next sought to determine the effect
of global HDAC inhibition on placenta 11𝛽-HSD2 protein
expression. We treated JEG-3 cells with SAHA, a competitive
inhibitor of both class I and class II HDACs [27]. An initial
dose response experiment was carried out 24 hours after
seedingwhere JEG-3 cells were treatedwith concentrations of
SAHA rangingwithin 1–10 𝜇Mfor 24 h, followed by immuno-
cytochemical staining for 11𝛽-HSD2. The relative expression
of 11𝛽-HSD2 protein was quantified using densitometry.
A one-way ANOVA revealed a significant overall effect of
SAHA treatment on 11𝛽-HSD2 expression (𝐹(3,8) = 5.5,
𝑝 = 0.02). Tukey’s post hoc test revealed a significance
difference between the vehicle and 10 𝜇M SAHA group (𝑝 <
0.05) (Figure 2(a)). As the effects of SAHA were significant
at 10 𝜇M, we also immunocytochemically stained for p-Ac-
histone H3 (S11/K15) (pAcH3) in this group and found a
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Figure 3: Class-specific HDACs on 11𝛽-HSD2 regulation in the placenta. (a) Expression data from the BioGPS database showing the relative
expression of class I HDAC, HDAC 1 in the placenta (red) relative to multiple human tissues and fetal brain. Graphical representation of
(b) 11𝛽-HSD2 and (c) AcH3 expression in JEG-3 cells treated with 0–10𝜇M of class I HDAC inhibitor MS275 for 24 h. (d) Representative
photomicrographs of JEG-3 cells immunocytochemically stained for 11𝛽-HSD2 and AcH3 after treatment with (0–10 𝜇M) MS275 for 24 h.
(e) Expression data from the BioGPS database showing the relative expression of class II HDAC, HDAC 5 in the placenta (red) relative to
multiple human tissues and fetal brain. Graphical representation of (f) 11𝛽-HSD2 and (g) AcH3 expression in JEG-3 cells treated with 0–
10mM of class IIa HDAC inhibitor MC1568 for 24 h. Data are expressed as mean ± SEM. (h) Representative photomicrographs of JEG-3 cells
immunocytochemically stained for 11𝛽-HSD2 and AcH3 after treatment with (0–10 𝜇M)MC1568 for 24 h. Data are expressed as mean ± SEM
(∗∗∗𝑝 < 0.001 compared to 0𝜇M; (b, f) one-way ANOVA with post hoc Tukey’s and (c, g) unpaired Student’s 𝑡-test; 25 cells per group per
experiment;𝑁 = 3). Scale bar = 50 𝜇m.
significant increase in the levels of pAcH3 in cells treated with
10 𝜇M SAHA for 24 h (𝑝 < 0.001) (Figure 2(b)). Overall,
these data indicate that pan-HDAC inhibition increases the
levels of pAcH3 (which has been shown to correlate with gene
expression) and 11𝛽-HSD2 expression in JEG-3 cells.
3.3. Class-Specific HDAC Inhibitors (HDI) Promote 11𝛽-HSD2
Expression in JEG-3 Cells. We next investigated if the effects
of pan-HDAC inhibition on 11𝛽-HSD2 expression were class-
specific using a class I-specific HDI (MS275) [28] and a class
IIa-specificHDI (MC1568) [29]. JEG-3 cells were treatedwith
increasing concentrations (0–10 𝜇M) of MS275 or MC1568
for 24 h before being immunocytochemically stained for
11𝛽-HSD2 and quantified using densitometry. A one-way
ANOVA revealed a significant overall effect of both MS275
(𝐹(3,8) = 95.89, 𝑝 < 0.0001) and MC1568 (𝐹(3,8) =
53.69, 𝑝 < 0.0001) treatment. Tukey’s post hoc test showed
that MS275 or MC1568 promoted a significant increase in
11𝛽-HSD2 protein expression with a significant difference
observed between the control and HDI-treated groups at
concentrations of 1𝜇M (𝑝 < 0.05), 5 𝜇M (𝑝 < 0.0001), and
10 𝜇M(𝑝 < 0.0001) (Figures 3(b) and 3(f)).We also examined
pAcH3 levels using densitometry and found a significant
increase in the levels of pAcH3 in cells treated with 10𝜇M
MC1568 or MS275 for 24 h (𝑝 < 0.001) (Figures 3(c) and
3(g)). These data show that class I and class IIa inhibition can
promote 11𝛽-HSD2 protein expression in JEG-3 cells.
3.4. Cortisol and IL-1𝛽 Decrease 11𝛽-HSD2 Expression Which
Is Prevented by MC1568. Given that alterations in placental
HSD11B2 expression are seen in pregnancies complicated
with stress or infection [5, 7], we next sought to determine
if the biological mediators of stress (Cort) and infection
(IL-1𝛽) altered 11𝛽-HSD2 protein expression at the cellular
level. Having confirmed using immunocytochemistry that
the glucocorticoid receptor (GR) and interleukin 1 receptor,
type I (IL1R1), were expressed in JEG-3 cells (Figure 4(a)),
we carried out an MTT assay to establish a concentration of
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Figure 4: Cortisol and IL-1𝛽 response in JEG-3 cells. (a) Representative photomicrographs of JEG-3 cells immunocytochemically stained for
the glucocorticoid receptor (GR; green) and (c) the interleukin 1 receptor, type I (IL-1R1; red). The second panel shows the corresponding
DAPI stained image. (b, c) MTT assay examining the viability of JEG3 cells treated with either 0–10 𝜇M cortisol (b) or 0–100 ng/ml IL-1𝛽
(c) for 24 h in vitro. (d) Graphical representation showing the levels 11𝛽-HSD2 in JEG-3 cells exposed to a vehicle (control), 10 ng/ml IL-1𝛽
or 2 𝜇M cortisol for 24 h. Data are expressed as mean ± SEM (∗𝑝 < 0.05 compared to 0𝜇M, ∗∗∗𝑝 < 0.001 compared to control; one-way
ANOVA with post hoc Tukey’s; (d) 100 cells per group per experiment;𝑁 = 3). Scale bar = 50 𝜇m.
Cort and IL-1𝛽 that did not affect cell viability. JEG-3 cells
were treated with Cort (0–10 𝜇M) or IL-1𝛽 (0–100 ng/ml) for
24 h and MTT assays were performed. An ANOVA showed
an overall effect of Cort and IL-1𝛽 treatment on cell viability,
with a difference observed with 10𝜇M Cort (Figure 4(b))
and 100 ng/ml IL-1𝛽 (Figure 4(c)) groups (𝑝 < 0.05). JEG-
3 cells were then treated with 2𝜇M of Cort or 10 ng/ml IL-
1𝛽 (concentrations that did not affect cell viability) for 24 h
before being fixed and immunocytochemically stained for
11𝛽-HSD2. Using densitometry, we observed a reduction in
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Figure 5: SAHA, MS275, and MC1568 prevent cortisol and IL1𝛽-induced decreases in 11𝛽-HSD2 expression. Graphical representation and
11𝛽-HSD2 expression in JEG-3 cells treated with 2𝜇MCort or 10 ng/ml IL-1𝛽 in the presence or absence of 10𝜇M SAHA (a, d), MS275 (b, e),
or MC1568 (c, f) for 24 h. Data are expressed as mean ± SEM. (∗∗∗𝑝 < 0.001 compared to DMSO; one-way ANOVA with post hoc Tukey’s
test; 25 cells per group per experiment;𝑁 = 3.)
11𝛽-HSD2 protein expression following exposure to Cort and
IL-1𝛽 (Figure 4(d)).
3.5. HDIs Can Restore 11𝛽-HSD2 Expression in an Environ-
ment of Stress and Inflammation. After identifying Cort and
IL-1𝛽 as potential biological mediators causing a decrease in
11𝛽-HSD2 protein expression, we next aimed to determine
if HDIs could counteract these effects of cortisol and IL-
1𝛽 on 11𝛽-HSD2 protein expression. After plating for 24
hours, JEG-3 cells were treatedwith 10 𝜇Mof SAHA,MC1568,
or MS275 followed by cortisol or IL-1𝛽 before being fixed
and immunocytochemically stained for 11𝛽-HSD2 protein.
Densitometry revealed that pretreatment of JEG-3 cells with
nonspecific inhibitor SAHA attenuated the effect of IL-1𝛽 and
Cort (SAHA: 2.8±0.15; SAHA+ IL-1𝛽: 3.0±0.2; SAHA+Cort:
3.350±0.19) (Figures 5(a) and 5(d)) on 11𝛽-HSD2 expression.
Similarly, treatment of JEG-3 cells with either class I-specific
HDI, MS275 (MS275: 2.2 ± 0.06; MS275 + IL-1𝛽: 3.18 ± 0.06;
MS275 + Cort: 2.2±0.09) (Figures 5(b) and 5(e)), or class IIa-
specific HDI MC1568 (MC1568: 1.8 ± 0.08; MC1568 + IL-1𝛽:
2.3 ± 0.1; MC1568 + Cort: 1.4 ± 0.07) (Figures 5(c) and 5(f))
was sufficient to attenuate the effect of both Cort and IL-1𝛽
on 11𝛽-HSD2 expression. These data show that exposure to
heightened levels of Cort and IL-1𝛽 can reduce the levels of
11𝛽-HSD2 protein in JEG-3 cells and that this effect that can
be prevented by HDAC inhibition.
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4. Discussion
The aim of this study was to examine the role of epigenetic
regulators in the control of 11𝛽-HSD2 protein expression in
placental cells. We used the in vitro placental model JEG-3
cells, as, despite their limitations, they are a well-established
cell line commonly used to mimic placental trophoblast cells
[30]. We employed pharmacological inhibitors of HDACs
to modulate histone acetylation and examined the impact
of this on 11𝛽-HSD2 protein expression. Finally, to assess
the potential of these compounds to regulate 11𝛽-HSD2
expression under conditions of stress and inflammation, cells
were exposed to biological mediators of these conditions,
namely, exogenous cortisol and IL-1𝛽.
HSD11B2 has previously been shown to localise in
trophoblast cells, with highest expression observed in the
syncytiotrophoblast [31, 32]. In line with these studies, we
demonstrated that 11𝛽-HSD2 protein is strongly expressed
in the term human placenta. To model trophoblast cells in
vitro, we used the human choriocarcinoma cell line, JEG-
3 cells. We found that these cells express HSD11B2 mRNA
making them a useful and convenient model to examine the
molecular mechanisms that regulate 11𝛽-HSD2 expression.
Using the BioGPS database, we demonstrated high
expression of class 1 HDACs 1, 2, 3, and 8 and class 2
HDACs 5, 4, 7, and 9, suggesting a role for HDAC proteins
in the placenta. Based on these findings, we used a SAHA,
a pan-HDAC inhibitor, and demonstrated a dose-dependent
increase in 11𝛽-HSD2 protein expression. To confirm that the
increase in 11𝛽-HSD2 protein expression was paralleled by
an increase in histone acetylation, we immunocytochemically
stained the cells for AcH3 and showed a similar dose-
dependent increase AcH3. This is in contradiction to previ-
ous studies, where HSD11B2 expression was reported to be
unchanged in JEG-3 cells following treatment with broad-
spectrum class I and class II inhibitor trichostatin A [24].
However, the dose of TSA (300 nm) used in these studies
was much smaller than the dose at which we observed an
effect (10 uM) and we have identified that the effect of HDAC
inhibition on 11𝛽-HSD2 expression is dose-dependent.
HDACs play a diverse role during fetal development
[26]. Global knockdown of HDAC3 [33] HDAC1 [34] and
HDAC7 [34] results in fetal lethality; however, mice lacking
HDAC6 develop normally [35]. HDACs have also been
shown to be important regulators of placental develop-
ment as inhibition of class II HDACs has been shown to
impair trophoblast differentiation through interactions with
Hypoxia-inducible factor [36]. Additionally, interaction of
HDACs with the STAT-1 TF may contribute to inhibition
of IFN-𝛾-inducible gene expression in trophoblast cells,
thereby protecting the placenta cells from maternal immune
rejection and contributing to a successful pregnancy [37].
This broad range of functions of HDACs suggests that global
inhibition could result in detrimental effects; therefore, a
more specific inhibition could represent an optimal method
for modifying 11𝛽-HSD2 expression. To determine if HDAC
regulation of 11𝛽-HSD2 protein expression is class-specific,
we used class-specific pharmacological HDAC inhibitors.We
observed a similar increase in 11𝛽-HSD2 protein expression
with class-specific inhibition of either class I or class IIa
HDACs, suggesting that many HDACS are likely involved in
regulating 11𝛽-HSD2 protein expression. Whilst this is the
first study to examine the effects of class-specific inhibitors
on HSD11B2 expression, it is interesting to note that previous
studies have demonstrated a class-specific effect of HDACs
on the regulation of other placental genes. Specifically, matrix
metalloproteinase 9 has been shown to be regulated by class
II but not class I HDACs [38].
Placental HSD11B2 has been shown to be reduced in a
number of adverse pregnancy conditions including anxiety,
stress, and infection [5–7]. As elevations in proinflammatory
cytokines and steroids are observed in these conditions [39,
40], we used cortisol and IL-1𝛽 to mimic an environment of
stress and inflammation. We have previously demonstrated
a reduction in 11𝛽-HSD2 protein expression in JEG-3 cells
following administration of IL-1𝛽 [7]. In this study, we also
report a decrease in 11𝛽-HSD2 expression following cortisol
administration. In contrast, Ni and colleagues have previ-
ously shown an increase in 11𝛽-HSD2 expression in primary
human trophoblast cells exposed to Cort [17]. However,
this study used primary cells which highlights the need for
further study of these questions in primary trophoblast cells.
Additionally, the maximum dose of cortisol used was 1 𝜇M,
whereby we observed a decrease at 2 𝜇M. It is possible that
cortisol may act in an adaptive way to induce 11𝛽-HSD2,
thereby protecting the fetus from high maternal glucocor-
ticoids but, at a certain threshold cortisol, may begin to
negatively impact 11𝛽-HSD2 expression. Interestingly, broad
or either class-specific HDAC inhibitors were sufficient to
prevent the cortisol and IL-1𝛽-induced decreases in 11𝛽-
HSD2 expression. This raises the possibility of targeting
key epigenetics modulators to protect the fetal glucocorti-
coid barrier and untimely fetal glucocorticoid overexposure.
However, given the critical role of epigenetic marks in fetal
development, nonspecific inhibition of HDACs, even at class
level, could produce detrimental effects on fetal development;
therefore, identifying more specifically the precise epigenetic
mechanismmediatingHSD11B2 regulation using knockdown
or overexpression of individual HDACs would allow the
development of a more targeted approach. The advancement
of targeted nanoparticles to deliver chemotherapeutic agents
directly to the placenta represents an exciting new avenue
to alter placental epigenetic mediators without interfering
with the fetus [41]. Notably, we also observe potentiation of
the effects of SAHA on HSD11B2 expression when admin-
istered with cortisol. Once activated, the GR can bind to
many coactivator proteins with known HAT activity [42].
The combined inhibition of HDACs by SAHA with the
potential increase in HAT activity caused by GR activation
from exogenous cortisol may explain this enhanced 11𝛽-
HSD2 protein expression.This relationship further highlights
the complexity of 11𝛽-HSD2 regulation and the epigenetic
landscape and confirms the need for more studies examining
how placental 11𝛽-HSD2 protein is controlled under both
basal and pathological conditions.
Here, we provide evidence of a role for histone acetylation
in the regulation of 11𝛽-HSD2 in the placenta; a limitation
is that the present study used JEG-3 cells. Although we
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confirmed 11𝛽-HSD2 to be abundantly expressed in this cell
line and that HSD11B2 levels are comparable between JEG-
3 cells and the human placenta, there are potential caveats
associated with using JEG-3 cells [43]. As such replicating
the current study in primary trophoblasts will help to clarify
the functional role of HDACs in the regulation of 11𝛽-HSD2
protein expression in the placenta. However, the present
study demonstrates a role for HDACs in the regulation of a
key enzyme that maintains the fetal glucocorticoid barrier
under basal and pathological conditions. It is likely that
a combination of different epigenetic modifiers including
HDACs are involved in regulating 11𝛽-HSD2 expression. As
HDACs have a broad role in regulating fetal development,
inhibition of all HDACs could be detrimental to the develop-
ing fetus.Therefore, unravelling the role of individualHDACs
in 11𝛽-HSD2 regulation, usingmore specific pharmacological
inhibitors or targeted knockdown of HDACs, will be crucial
to understanding the epigenetic mechanisms that regulate
11𝛽-HSD2 expression and for developing novel protective
pharmacotherapies for the human placenta.
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